Literature DB >> 29954929

Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia.

Chezi Ganzel1, Mira Kharit2, Chen Duksin3, Jacob M Rowe2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29954929      PMCID： PMC6165821          DOI： 10.3324/haematol.2018.197640

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  2 in total

1.  Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.

Authors:  Karen L Bride; Tiffaney L Vincent; Soo-Yeon Im; Richard Aplenc; David M Barrett; William L Carroll; Robin Carson; Yunfeng Dai; Meenakshi Devidas; Kimberly P Dunsmore; Tori Fuller; Tina Glisovic-Aplenc; Terzah M Horton; Stephen P Hunger; Mignon L Loh; Shannon L Maude; Elizabeth A Raetz; Stuart S Winter; Stephan A Grupp; Michelle L Hermiston; Brent L Wood; David T Teachey
Journal:  Blood       Date:  2018-01-05       Impact factor: 22.113

2.  Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.

Authors:  Anna Oberle; Anna Brandt; Malik Alawi; Claudia Langebrake; Snjezana Janjetovic; Christine Wolschke; Kerstin Schütze; Peter Bannas; Nicolaus Kröger; Friedrich Koch-Nolte; Carsten Bokemeyer; Mascha Binder
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941
  2 in total
  10 in total

Review 1.  Complement System: a Neglected Pathway in Immunotherapy.

Authors:  Anne Bordron; Cristina Bagacean; Adrian Tempescul; Christian Berthou; Eléonore Bettacchioli; Sophie Hillion; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

2.  CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.

Authors:  Sarah Leong; Sarah Inglott; Foteini Papaleonidopoulou; Karen Orfinada; Philip Ancliff; Jack Bartram; Ben Carpenter; Adele K Fielding; Sara Ghorashian; Victoria Grandage; Rajeev Gupta; Rachael Hough; Asim Khwaja; Vesna Pavasovic; Anupama Rao; Sujith Samarasinghe; Ajay Vora; Marc R Mansour; David O'Connor
Journal:  Blood Adv       Date:  2020-10-13

Review 3.  Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.

Authors:  Bachar Samra; Elias Jabbour; Farhad Ravandi; Hagop Kantarjian; Nicholas J Short
Journal:  J Hematol Oncol       Date:  2020-06-05       Impact factor: 17.388

Review 4.  Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

Authors:  Veronica A Guerra; Elias J Jabbour; Farhad Ravandi; Hagop Kantarjian; Nicholas J Short
Journal:  Ther Adv Hematol       Date:  2019-05-19

5.  Approach to the Adult Acute Lymphoblastic Leukemia Patient.

Authors:  Valentina Sas; Vlad Moisoiu; Patric Teodorescu; Sebastian Tranca; Laura Pop; Sabina Iluta; Sergiu Pasca; Cristina Blag; Sorin Man; Andrei Roman; Catalin Constantinescu; Ioana Rus; Mihail Buse; Bogdan Fetica; Mirela Marian; Cristina Selicean; Ioana Berindan-Neagoe; Bobe Petrushev; Horia Bumbea; Alina Tanase; Mihnea Zdrenghea; Shigeo Fuji; Shigehisa Kitano; Ciprian Tomuleasa
Journal:  J Clin Med       Date:  2019-08-06       Impact factor: 4.241

6.  Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.

Authors:  Marco Cerrano; Massimiliano Bonifacio; Matteo Olivi; Antonio Curti; Michele Malagola; Michelina Dargenio; Anna Maria Scattolin; Cristina Papayannidis; Fabio Forghieri; Carmela Gurrieri; Ilaria Tanasi; Patrizia Zappasodi; Roberta La Starza; Nicola Stefano Fracchiolla; Patrizia Chiusolo; Luisa Giaccone; Maria Ilaria Del Principe; Fabio Giglio; Marzia Defina; Claudio Favre; Carmelo Rizzari; Barbara Castella; Giovanni Pizzolo; Felicetto Ferrara; Sabina Chiaretti; Robin Foà
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

Review 7.  A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies.

Authors:  Haley Newman; David T Teachey
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

Review 8.  Targeting CD38 in Neoplasms and Non-Cancer Diseases.

Authors:  Wojciech Szlasa; Jakub Czarny; Natalia Sauer; Katarzyna Rakoczy; Natalia Szymańska; Jakub Stecko; Maksymilian Kołodziej; Maciej Kaźmierczak; Ewa Barg
Journal:  Cancers (Basel)       Date:  2022-08-28       Impact factor: 6.575

Review 9.  Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities.

Authors:  Lukasz Komorowski; Klaudyna Fidyt; Elżbieta Patkowska; Malgorzata Firczuk
Journal:  Int J Mol Sci       Date:  2020-08-12       Impact factor: 5.923

10.  Daratumumab: new indications revolving around "off-targets".

Authors:  Yishai Ofran
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.